Related references
Note: Only part of the references are listed.Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
mTOR-Dependent Regulation of PHLPP Expression Controls the Rapamycin Sensitivity in Cancer Cells
Jianyu Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Anne-Christine Piguet et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
Fang-Ming Gu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Sirolimus-Based Immunosuppression Is Associated with Increased Survival After Liver Transplantation for Hepatocellular Carcinoma
Christian Toso et al.
HEPATOLOGY (2010)
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle
Sherrie Bhoori et al.
JOURNAL OF HEPATOLOGY (2010)
Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular Carcinoma
Marco Vivarelli et al.
TRANSPLANTATION (2010)
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report
Yubao Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines
Rosa H. Jimenez et al.
PLOS ONE (2009)
Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors Reassessment of Risk Factors for Tumor Recurrence
Marco Vivarelli et al.
ANNALS OF SURGERY (2008)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Arkaitz Carracedo et al.
CELL CYCLE (2008)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
Anne-Christine Piguet et al.
JOURNAL OF HEPATOLOGY (2008)
Sirolimus-Based Immunosuppression Therapy in Liver Transplantation for Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria
J. Zhou et al.
TRANSPLANTATION PROCEEDINGS (2008)
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Hongbing Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Predicted mechanisms of resistance to mTOR inhibitors
R. T. Kurmasheva et al.
BRITISH JOURNAL OF CANCER (2006)
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience
Jian Zhou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?
M Schwartz et al.
JOURNAL OF HEPATOLOGY (2005)
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
OJ Shah et al.
CURRENT BIOLOGY (2004)
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis
BD Manning
JOURNAL OF CELL BIOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
HB Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
p73 independent of c-Myc represses transcription of platelet-derived growth factor β-receptor through interaction with NF-Y
A Hackzell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Mechanisms of resistance to rapamycins
S Huang et al.
DRUG RESISTANCE UPDATES (2001)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Share Paper
